Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPHW) Sees Significant Decline in Short Interest

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPHW) was the recipient of a significant drop in short interest in the month of December. As of December 31st, there was short interest totalling 3,500 shares, a drop of 73.5% from the December 15th total of 13,200 shares. Based on an average daily trading volume, of 33,700 shares, the short-interest ratio is presently 0.1 days.

Reviva Pharmaceuticals Trading Down 16.7 %

NASDAQ RVPHW traded down $0.06 during mid-day trading on Tuesday, hitting $0.28. The company’s stock had a trading volume of 54,193 shares, compared to its average volume of 52,295. Reviva Pharmaceuticals has a 52-week low of $0.07 and a 52-week high of $1.20. The stock’s fifty day simple moving average is $0.21 and its two-hundred day simple moving average is $0.17.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals Holdings, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is brilaroxazine (RP5063), which is in Phase III clinical trials for use in the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis.